DJIA 18,010.68 -115.44 -0.64%
NASDAQ 5,070.03 -27.95 -0.55%
S&P 500 2,107.39 -13.40 -0.63%
market minute promo

BioMarin Pharmaceutical (NASDAQ: BMRN)

125.57 -1.82 (-1.43%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BMRN $125.57 -1.43%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $127.73
Previous Close $127.39
Daily Range $124.20 - $127.82
52-Week Range $55.36 - $133.54
Market Cap $20.1B
P/E Ratio -119.06
Dividend (Yield) $0.00 (0.0%)
Volume 1,650,610
Average Daily Volume 1,202,113
Current FY EPS -$2.14




Drug Makers

BioMarin Pharmaceutical (BMRN) Description

The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. Website:

News & Commentary Rss Feed

Pfizer's Monstrous Clinical Pipeline Is Harboring 2 Hidden Gems

Pfizer's mind-boggling size often results in promising clinical candidates getting swept under the rug, so to speak. Here is a look at two of the pharma giant's orphan drug candidates that haven't generated much talk among investors, despite being potential game-changers for their target indications.

Retrophin Soars on $245M Priority Review Voucher Sale - Analyst Blog

'Mad Money' Lightning Round: Buy, Buy, Buy Yahoo!, Not Alibaba

Play Alibaba Through Yahoo - Cramer's Lightning Round (5/27/15)

Wednesday's ETF Movers: BBH, XOP

Insider Trading Alert - WASH, BMRN And AAP Traded By Insiders

Did BioMarin Bet on the Wrong Experimental DMD Drug?

Sarepta Therapeutics may hold a key advantage over BioMarin in the race to bring a game-changing Duchenne muscular dystrophy drug to market. Here's why.

Analyst Has 4 Top US Growth Stock Calls for This Week

Merck KGaA-BioMarin's Kuvan may Undergo Label Update - Analyst Blog

Merck KGaA-BioMarin's Kuvan may Undergo Label Update - Analyst Blog

See More BMRN News...

BMRN's Top Competitors

BMRN $125.57 (-1.43%)
Current stock: BMRN
AMGN $156.26 (-0.69%)
Current stock: AMGN
GILD $112.27 (-0.51%)
Current stock: GILD
BIIB $396.99 (-0.78%)
Current stock: BIIB